Replies to post #12295 on Innovus Pharmaceuticals Inc. (fka INNV)

[healthywelth]

Nice Reminder -You will be rewarded if you are willing to give this company time to continue to expand and become profitable by end of 2018.

FlutiCare has a unique sales platform and they are potentially touching millions of people that Flonase and ClariSpray do not have. Just wait for the next allergy and hay fever season to start in March/April.

Also love the continued reduction of expenses. I think the CEO is pretty determined to get to profitability and he is almost there. They missed EPS by 0.04 in Q3 2016 and missed by 0.01 this Q3. I am encouraged that they are increasing revenues YOY. Even if they don't get to the $10 million guidance for 2017, they are still going to double the $4.8 million 2016 total revenue with a lot less expenses, more cash on-hand, less debt. I agree that meeting guidance is important but they don't have the institutional investors yet so I don't expect Wall Street to be punitive. Syd all time right ....................

[jtaylor68]

No way, Shawn. Q3 revenues have been very negatively impacted by the natural disasters in Florida and Texas. Additionally, this annoying counterfeit issue their South Korean distributor has to deal with led to no revenues being book from their agreement. We are talking about $700k - $1M in revenue loss due to these circumstances which are obviously outside of management control.

Under normal circumstances this quarter could have generated close to or even more than $3M in revenues.